Benjamin Edwards Inc. Buys 11,829 Shares of Medtronic PLC $MDT

Key Points

• Benjamin Edwards Inc. increased its Medtronic position by 4.9% in the second quarter, purchasing 11,829 shares for a total holding of 253,015 shares valued at approximately $19.8 million. Institutional investors collectively own 82.06% of the company.
• Medtronic exceeded its latest quarterly estimates with adjusted EPS of $1.55 and revenue of $9.81 billion, while revenue grew 9.9% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $99.79, although tariffs and currency movements remain risks.
• The company declared a quarterly dividend of $0.72 per share, equivalent to an annualized $2.88 payout and a 3.2% yield. Shares opened at $91.28, and investors are watching upcoming results and fiscal 2027 guidance for evidence that Medtronic’s rebound is sustainable.

Benjamin Edwards Inc. lifted its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 253,015 shares of the medical technology company's stock after buying an additional 11,829 shares during the period. Benjamin Edwards Inc.'s holdings in Medtronic were worth $19,794,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MDT. Monetary Solutions Ltd acquired a new position in Medtronic during the fourth quarter valued at approximately $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Acumen Wealth Advisors LLC bought a new stake in shares of Medtronic during the 4th quarter worth approximately $29,000. Imprint Wealth LLC bought a new stake in shares of Medtronic during the 3rd quarter worth approximately $31,000. Finally, Basepoint Wealth LLC acquired a new stake in shares of Medtronic in the 4th quarter valued at approximately $32,000. Institutional investors own 82.06% of the company's stock.

Insider Activity

In related news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company's stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.27% of the company's stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Medtronic Trading Up 1.5%

Shares of NYSE:MDT opened at $91.28 on Friday. The business's 50 day simple moving average is $85.57 and its 200 day simple moving average is $85.67. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The company has a market capitalization of $116.84 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.45 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to analysts' expectations of $9.62 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic's revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the business earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. Medtronic's dividend payout ratio (DPR) is currently 77.21%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Evercore set a $105.00 target price on shares of Medtronic in a research note on Monday, July 6th. BTIG Research reaffirmed a "buy" rating and set a $91.00 price target on shares of Medtronic in a research report on Tuesday, August 18th. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $100.00 to $86.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. The Goldman Sachs Group decreased their price objective on shares of Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research report on Thursday, June 4th. Finally, UBS Group raised shares of Medtronic from a "neutral" rating to a "buy" rating and upped their target price for the company from $85.00 to $100.00 in a report on Tuesday, July 28th. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $99.79.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source